email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1426 - 1440
of 3615 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Wuhan ABconal Acquires Boston mAb Drug Developer Yurogen
$5.00
Available
Kintor OK'd to Start US Trial of Androgen Receptor Antagonist for COVID-19
$5.00
Available
GenSciences Raises $124 Million for New Drug Development
$5.00
Available
Apollomics Starts China Trial of Immunotherapy for AML
$5.00
Available
SciClone IPOs on Hong Kong Exchange, Raising $279 Million
$5.00
Available
Biotheus Completes $100 Million Funding for Biologic Drugs
$5.00
Available
Innoforce and dMed Team Up to Develop/Manufacture Novel Biologics
$5.00
Available
WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO
$5.00
Available
LianBio Acquires China Rights to ReViral's RSV Therapy in $119 Million Deal
$5.00
Available
Innovent Starts US Trial of CD47/PD-L1 Bispecific Antibody
$5.00
Available
OrbiMed, a Life Sciences Investor, Raises $800 Million for Asia Partners IV
$5.00
Available
Suzhou Medilink Closes Initial $50 Million Funding for ADC Drugs
$5.00
Available
Junshi Out-Licenses Partial China Marketing Rights for PD-1 to AstraZeneca
$5.00
Available
Junshi Bio's PD-1 Approved as First-line Therapy for Nasopharyngeal Carcinoma
$5.00
Available
Harbour BioMed OK'd to Start China Trial of CTLA-4 Antibody for NSCLC
$5.00
Available